Canonical Wnt Pathway Is Involved in Chemoresistance and Cell Cycle Arrest Induction in Colon Cancer Cell Line Spheroids
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24065252 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Angela Patricia Moreno-Londoño und 4 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Bioquímica, Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), Mexico City 04510, Mexico. Hauptthemen laut MEDLINE: Colonic Neoplasms, Colorectal Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidad Nacional AUtónoma de México, Consejo Nacional de Ciencia y Tecnología, CONACYT.
Abstract (Originalsprache)
The presence of cancer stem cells (CSCs) has been associated with the induction of drug resistance and disease recurrence after therapy. 5-Fluorouracil (5FU) is widely used as the first-line treatment of colorectal cancer (CRC). However, its effectiveness may be limited by the induction of drug resistance in tumor cells. The Wnt pathway plays a key role in the development and CRC progression, but it is not clearly established how it is involved in CSCs resistance to treatment. This work aimed to investigate the role played by the canonical Wnt/β-catenin pathway in CSCs resistance to 5FU treatment. Using tumor spheroids as a model of CSCs enrichment of CRC cell lines with different Wnt/β-catenin contexts, we found that 5FU induces in all CRC spheroids tested cell death, DNA damage, and quiescence, but in different proportions for each one: RKO spheroids were very sensitive to 5FU, while SW480 were less susceptible, and the SW620 spheroids, the metastatic derivative of SW480 cells, displayed the highest resistance to death, high clonogenic capacity, and the highest ability for regrowth after 5FU treatment. Activating the canonical Wnt pathway with Wnt3a in RKO spheroids decreased the 5FU-induced cell death. But the Wnt/β-catenin pathway inhibition with Adavivint alone or in combination with 5FU in spheroids with aberrant activation of this pathway produced a severe cytostatic effect compromising their clonogenic capacity and diminishing the stem cell markers expression. Remarkably, this combined treatment also induced the survival of a small cell subpopulation that could exit the arrest, recover SOX2 levels, and re-grow after treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departamento de Bioquímica, Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), Mexico City 04510, Mexico.
- Instituto de Fisiología Celular, Universidad Nacional Autónoma de México (UNAM), Mexico City 04510, Mexico.
ORCID-Profile: Marina Macías-Silva, Martha Robles-Flores
Förderung
- Universidad Nacional AUtónoma de México
- Consejo Nacional de Ciencia y Tecnología
- CONACYT
Zitieren
APA
Moreno-Londoño, A. P., Castañeda-Patlán, M. C., Sarabia-Sánchez, M. A., Macías-Silva, M., & Robles-Flores, M. (2023). Canonical Wnt Pathway Is Involved in Chemoresistance and Cell Cycle Arrest Induction in Colon Cancer Cell Line Spheroids. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24065252
Vancouver
Moreno-Londoño AP, Castañeda-Patlán MC, Sarabia-Sánchez MA, Macías-Silva M, Robles-Flores M. Canonical Wnt Pathway Is Involved in Chemoresistance and Cell Cycle Arrest Induction in Colon Cancer Cell Line Spheroids. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24065252
BibTeX
@article{MorenoLondoo2023,
author = {Moreno-Londoño, Angela Patricia and Castañeda-Patlán, María Cristina and Sarabia-Sánchez, Miguel Angel and Macías-Silva, Marina and Robles-Flores, Martha},
title = {Canonical Wnt Pathway Is Involved in Chemoresistance and Cell Cycle Arrest Induction in Colon Cancer Cell Line Spheroids},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24065252}
}
EUVIMED